A rare example of nickel(ii) chains based on a heteroscorpionate-like ligand with quadruple imidazolyl interactions.

The first nickel(ii) complex with the heteroscorpionate-like bridging ligand DIMMAL (2-di1H-2-imidazolylmethylmalonate), [Ni(DIMMAL)(H2O)3]n·3nH2O (1), is a one-dimensional coordination polymer whose structure shows regular Ni(ii) chains with H-bonding inter-chain interactions and a rare example of a Quadruple Imidazolyl Embrace (QIE). The Ni(ii) chain shows a weak antiferromagnetic interaction that can be modelled with a regular S = 1 chain model including a zero field splitting with g = 2.270, J = -1.5 cm(-1) and D = -2.26 cm(-1).

Síndrome de Horner incompleto como signo de presentación de ependimoma del cuarto ventrículo / Incomplete Horner's syndrome as a presenting sign of fourth ventricle ependymoma

Caso clínico: Varón de 44 años con ptosis palpebral y neuralgia del trigémino como signo de presentación de un ependimoma del cuarto ventrículo. Después del tratamiento quirúrgico desarrolló una paresia residual del sexto par. Discusión: El síndrome de Horner aparece por la alteración de la inervación simpática del ojo y los anejos. Algunos tumores pueden ser la causa, en nuestro caso un ependimoma del cuarto ventrículo, que debutó de forma excepcional con ptosis palpebral y afectación de la división oftálmica del trigémino, debido a la proximidad de estas fibras nerviosas a nivel del troncoencéfalo (AU)

Case report: The case of 44 year old male patient with palpebral ptosis and trigeminal neuralgia as presenting sign of fourth ventricle ependymoma is reported. After surgical treatment, the patient developed a residual paresis of the sixth cranial nerve. Discussion: Horner's syndrome occurs due to an alteration of the sympathetic innervations of the eye and adnexa. Some tumours may be the cause, in our case an ependymoma of the fourth ventricle, which onset exceptionally with blepharoptosis and involvement of the ophthalmic division of trigeminal nerve, due to the proximity of these nerve fibres at the brainstem (AU)

[Incomplete Horner's syndrome as a presenting sign of fourth ventricle ependymoma]. / Síndrome de Horner incompleto como signo de presentación de ependimoma del cuarto ventrículo.

CASE REPORT: The case of 44 year old male patient with palpebral ptosis and trigeminal neuralgia as presenting sign of fourth ventricle ependymoma is reported. After surgical treatment, the patient developed a residual paresis of the sixth cranial nerve. DISCUSSION: Horner's syndrome occurs due to an alteration of the sympathetic innervations of the eye and adnexa. Some tumours may be the cause, in our case an ependymoma of the fourth ventricle, which onset exceptionally with blepharoptosis and involvement of the ophthalmic division of trigeminal nerve, due to the proximity of these nerve fibres at the brainstem.

Two polymeric compounds built from mononuclear and tetrameric squarate-copper(II) complexes by deprotonation of 3,3-bis(2-imidazolyl)propionic acid (HBIP). Synthesis, crystal structure, and magnetic characterization of [Cu(HBIP)(BIP)](C(4)O(4))(1/2).2H(2)O and [[Cu(BIP)(OH(2))](4)(mu-C(4)O(4))](ClO(4))(2).4H(2)O.

Two polynuclear copper(II)-squarate compounds of formulas [Cu(HBIP)(BIP)](C(4)O(4))(1/2).2H(2)O (1) and [[Cu(BIP)(OH(2))](4)(mu-C(4)O(4))](ClO(4))(2).4H(2)O (2) (HBIP = 3,3-bis(2-imidazolyl)propionic acid) have been synthesized and characterized by single-crystal X-ray diffraction. Both compounds crystallize in the triclinic system, space group P1, with a =7.947(1) A, b =12.327(4) A, c = 13.150(3) A, alpha = 113.91(2) degrees, beta = 99.85(2) degrees, gamma = 90.02(2) degrees for compound 1 and a = 8.010(1) A, b = 13.073(1) A, c = 14.561(1) A, alpha = 72.13(1) degrees, beta = 80.14(1) degrees, gamma = 84.02(1) degrees for compound 2. The structure of compound 1 can be viewed as made up of [Cu(HBIP)(BIP)] units linked together by the BIP carboxylate groups to form a one-dimensional chain structure along the a axis in the crystal. The copper ion is five-coordinated (CuN(4)O chromophore) with BIP and HBIP acting as tridentate and bidentate ligands, respectively. The coordination geometry is intermediate between SP and TBP. The structure of compound 2 is made of infinite chains built from cationic tetranuclear [[Cu(BIP)(OH(2))](4)(mu-C(4)O(4))](2+) complex units, two uncoordinated perchlorate anions, and four water molecules of crystallization. The squarato group bridges the copper(II) ions, while BIP acts as a tridentate ligand, connecting through its carboxylate group the tetrameric units along the a axis. The two crystallographically independent copper(II) ions are pentacoordinated within a distorted square-based pyramid. Electronic and EPR spectra are consistent with the crystallographic data. Both compounds follow a Curie-Weiss law with very low values of theta (-0.13 and +0.12 K). In compound 2, the weak ferromagnetism interaction is discussed on the basis of the structural features and correlated with published magnetostructural data on similar squarato-bridged copper(II) compounds.

Synthesis, Crystal Structure, and Magnetic Properties of Oxalato-Copper(II) Complexes with 3,3-Bis(2-imidazolyl)propionic Acid, an Imidazole-Carboxylate Polyfunctional Ligand: From Mononuclear Entities to Ladder-Like Chains.

The synthesis of five new Cu(II) compounds of formula [Cu(HBIP)(C(2)O(4))].H(2)O (1), [Cu(HBIP)(C(2)O(4))(OH(2))].2H(2)O (2), [{Cu(HBIP)Cl}(2)(&mgr;-C(2)O(4))].2H(2)O (3), [{Cu(BIP)}(2)(&mgr;-C(2)O(4))].2H(2)O (4) and [{Cu(BIP)}(2)(&mgr;-C(2)O(4))].6H(2)O (5), together with their spectral and magnetic characterization, is reported. Crystal structures of compounds 2, 3 and 5 have been solved. All these compounds crystallize in the triclinic system, space group P&onemacr;, with a = 7.3322(3) Å, b = 10.014(1) Å, c = 11.541(1) Å, alpha = 113.22(1) degrees, beta = 91.37(1) degrees, gamma = 94.51(1) degrees, Z = 2 for compound 2; a = 7.444(2) Å, b = 8.518(2) Å, c = 11.231(2) Å, alpha = 97.45(2) degrees, beta = 98.99(2) degrees, gamma = 97.95(2) degrees, Z = 1 for compound 3; and a = 7.977(1) Å, b = 8.656(1) Å, c = 11.807(1) Å, alpha = 69.06(1) degrees, beta = 86.07(1) degrees, gamma = 67.36(1) degrees, Z = 1 for compound 5. In compound 2 the asymmetric unit consists of one isolated neutral [Cu(HBIP)(C(2)O(4))(OH(2))] molecule and two noncoordinated water molecules. The Cu(II) ion is five-coordinated (4+1 coordination mode) with HBIP and oxalato entities acting as bidentate ligands and the water molecule as the fifth ligand. The structure of compound 3 is made up of centrosymmetric binuclear [{Cu(HBIP)(Cl)}(2)(&mgr;-C(2)O(4))] units and noncoordinated water molecules. The two copper atoms are linked through a bis-bidentate oxalato group leading to a metal-metal separation of 5.28(3) Å. The coordination stereochemistry of the CuN(2)O(2)Cl chromophore is approximately SP. Compound 5 exhibits a structure built of ladder-like chains. In these chains the rungs are constituted by the neutral dinuclear centrosymmetric [(BIP)Cu(C(2)O(4))Cu(BIP)] entities. The oxalato group bridges two copper atoms in a bis-bidentate fashion, whereas the BIP acts as a tridentate ligand, connecting through their carboxylate groups these dimeric units along the a axis. The copper atom is involved in a five-coordinated CuN(2)O(2)O' chromophore, with a coordination geometry intermediate between SP and TBP. The magnetic properties of all complexes have been investigated. Compound 1 and 2 follow a Curie-Weiss law with very low values of theta. The other three compounds exhibit an antiferromagnetic coupling, with 2J = -265 cm(-)(1) for 3, 2J = -108 cm(-)(1) for 4, and 2J = -5.7 cm(-)(1) for 5. The strength of the exchange interaction is discussed on the basis of the structural features and correlated with published magneto-structural data on similar oxalato-bridged copper(II) compounds.

Tolerance and efficacy of parenterally administered penicillin-streptomycin and orally administered amoxicillin or penicillin V for prophylaxis of experimentally induced streptococcal endocarditis.

A regimen of a single intramuscular dose of penicillin G-streptomycin was compared with regimens of three oral doses of amoxicillin and two oral doses of penicillin V to prevent Streptococcus sanguis endocarditis in rabbits with experimentally induced valvular heart lesions. Challenge doses of 10(4), 10(6), and 10(8) CFU of a strain of S. sanguis highly tolerant to penicillin and amoxicillin were used. The combination of penicillin and streptomycin was the only regimen tested that provided full protection even against the highest inoculum concentration. A single oral dose of penicillin V (36 mg/kg) or amoxicillin (50 mg/kg), two oral doses of penicillin V (36 and 18 mg/kg with a 7-h interval between doses), or six oral doses of amoxicillin (50 mg/kg followed by 8.5 mg/kg at 8-h intervals) protected recipients of the lowest inoculum concentration; protection diminished with increasing inocula. In contrast, administration of two high oral doses of amoxicillin (50 mg/kg) with a 10-h interval between doses provided full protection against challenge doses of 10(4) and 10(6) CFU, preventing endocarditis in 10 (66%) of 15 recipients of 10(8) CFU. All regimens evaluated were highly effective in preventing endocarditis when rabbits were challenged with 10(4) CFU. The combination of penicillin and streptomycin was the best regimen tested. Administration of two high oral doses of amoxicillin (50 mg/kg) with a 10-h interval between doses led to significantly fewer infections when compared with the other oral regimens when rabbits were challenged with 10(6) and 10(8) CFU.

Efficacy of orally administered penicillin V for prophylaxis of experimentally induced streptococcal endocarditis.

Four oral penicillin V regimens were compared for the ability to prevent Streptococcus sanguis infection of experimentally induced valvular heart lesions in rabbits. Challenge doses of 10(4), 10(6), and 10(8) CFU of a penicillin-susceptible strain of S. sanguis were used in this study. Measured by recovery of test organisms from endocardial lesions, the lowest-concentration inoculum was infective for 53% of the recipients; the higher-concentration inocula were infective for all recipients. A single-oral-dose penicillin V regimen (36 mg/kg of body weight) prevented endocarditis when rabbits were challenged with 10(4) CFU, but protection diminished with increasing inoculum concentrations. In contrast, addition of a second penicillin V dose (18 mg/kg of body weight) administered with a 7-h interval between doses achieved fully effective prophylaxis against even the highest inoculum tested (10(8) CFU). A repeated set of experiments in which half the dose of penicillin V was administered showed significantly reduced protection against S. sanguis endocarditis.

Comparative capacity of orally administered amoxicillin and parenterally administered penicillin-streptomycin to protect rabbits against experimentally induced streptococcal endocarditis.

A single-intramuscular-dose immunization regimen with a penicillin G-streptomycin combination was compared with three oral-dose amoxicillin regimens for the capacity to prevent Streptococcus sanguis infections of experimentally induced valvular heart lesions in rabbits. Challenge doses of 10(4), 10(6), and 10(8) CFU of a strain of S. sanguis equally susceptible to penicillin and amoxicillin were used in this study. Measured by recovery of test organisms from endocardial lesions, the lowest concentration of these inocula was infective for 60% of the recipients; the two higher-concentration inocula were infective for all recipients. The penicillin G-streptomycin combination provided complete protection against infection with inocula of all sizes. A single-oral-dose amoxicillin regimen (50 mg/kg of body weight) prevented endocarditis when rabbits were challenged with 10(4) CFU, but protection diminished with increasing inoculum concentrations. Similar results were achieved when five oral doses of amoxicillin (8.5 mg/kg of body weight) added at 8-h intervals were included in the single-oral-dose regimen. In contrast, when rabbits received two oral doses of amoxicillin (50 mg/kg of body weight) with a 10-h interval between doses, prophylaxis was fully effective with even the highest inoculum concentration.

[Acrodermatitis enteropathica: disparity between clinical features and zinc blood levels]. / Acrodermatitis enteropática: disparidad entre la clínica y los niveles plasmáticos de zinc.

A new case of acrodermatitis enteropathica in a 2.5 month old infant is presented. Oral administration of zinc sulfate (10 mg/kg/day) improved in a few days clinical and analytical pattern. In 1.5 months treatment was forsaken, reappearing after 22 days digestive and cutaneous symptoms. Serum zinc was then rather high (175 mcg/dl). Disparity between serum zinc and clinical features, suggest that in acrodermatitis enteropathica there is a lack in transport, not only in the enterocyte, but also in other cells of the body. Discerning dose and treatment duration must be assessed by clinical response rather than zinc serum level.